Solensia is administered by veterinary professionals. If you suspect your cat suffers from OA pain, ask your vet health team about Solensia.

In a clinical study, Solensia was shown to be well tolerated by cats. The most common adverse events reported in a clinical study were vomiting and injection site pain. Solensia may be associated with scabbing of the head and neck, dermatitis, and pruritus.⁷

As with all medicines, there are potential side effects. Talk to your veterinarian about the benefits and risks before starting your cat on any treatment.

Three out of every 4 cat caregivers saw improvement in signs of OA pain when their cats were treated monthly with Solensia in a 3-month study.⁷*

In a study, Solensia was shown to increase mobility in cats after a single treatment.^5†

*67% of cat owners experienced improvement in signs of their cat’s pain in the placebo group.
^†Individual results may vary.

As a monthly injection administered at your vet’s office, your vet will schedule an appointment every 4 weeks to administer treatment and reassess your cat's OA pain and mobility.

In a study, Solensia was shown to increase mobility after 3 doses, with some cats experiencing improvements with just 1 dose.⁵ As individual results will vary, it's best to talk with your vet health team to hear how Solensia is working in their patients.

At Zoetis, we take suspected AEs very seriously for all of our products, including Solensia. Our team of veterinary experts works alongside both pet owners and their attending veterinarians to understand each pet’s unique situation when brought to our attention. And we report every potential adverse event we receive directly to regulators like the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Zoetis also has systems in place to continuously monitor the volume and trends of adverse event reporting related to all of our veterinary medicines, including Solensia. In compliance with the law, we share these reports of aggregated case data to regulatory agencies around the world, and if a new safety signal emerges, we partner with regulatory authorities on appropriate actions, which could include amendment of our label as necessary to better inform veterinarians and pet owners of potential risks or safety concerns to mitigate risks to the pet.

While we report all AEs in full compliance with the law, we acknowledge that this information is imperfect, as reporting by pet owners and veterinarians is voluntary and we cannot confirm that all doses distributed have been administered, but it is the best post-launch indicator we or any other company has as to the rate of AEs occurring.

We encourage all pet owners who believe their pet may have had an adverse reaction to Solensia or any medication to contact their pet’s veterinarian first. Pet owners should contact Zoetis, and when they do, we document the conversation and make every effort to include the attending veterinarian in the conversation. This helps us fully understand each case and report the potential adverse effect to the appropriate regulatory body. We always encourage pet owners to also speak with their veterinarian for further consultation and advice after speaking with the Zoetis team.